Ave-Triin Tihamäe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ave-Triin Tihamäe has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Anni Lepland
Genetics and Personalized Medicine Clinic, Tartu University Hospital, 50406 Tartu, Estonia
2 shared publications - Dafydd Gareth Evans
Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK
2 shared publications - Eivind Hovig
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
2 shared publications - Filipa Sampaio
Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
2 shared publications - Gonçalo Nogueira-Costa
Medical Oncology Department, Unidade Local de Saúde Santa Maria, 1649-035 Lisboa, Portugal
2 shared publications - Inna Feldman
Department of Public Health and Caring Sciences, Uppsala University, 753 10 Uppsala, Sweden
2 shared publications
Latest Publications
- Open Access
Guidance for the Clinical Use of the Breast Cancer Polygenic Risk Scores
Background/Objectives: Polygenic risk scores (PRSs) have been extensively studied and are increasingly applied in healthcare. One of the most studied and developed areas is predictive medicine for breast cancer, but there is no wider consensus on the indications for the clinical use of PRSs for breast cancer. This current guidance endeavours to articulate the scientific evidence underpinning the clinical utility of PRSs in stratifying breast cancer risk, with a particular emphasis on clinical application. Methods: This guidance has been prepared by a group of experts who have been active in breast cancer PRS research and development, combining a review of the evidence base with expert opinion for indications for clinical use. Results: Based on data from various studies and existing breast cancer prevention and screening services, the indications for clinical use of breast cancer PRSs can be divided into the following scenarios: (1) Management of cancer-free women with a family history of cancer; (2) individual personalised breast cancer prevention and screening in healthcare services; and (3) breast cancer screening programs for more personalised screening. Conclusions: The integration of PRSs into clinical practice enables healthcare providers to deliver more accurate risk assessments, personalised prevention strategies, and optimised screening programmes, thereby improving patient outcomes and enhancing the effectiveness of breast cancer care. PRS testing represents a novel component in clinical breast cancer risk assessment, supporting a personalised, risk-based approach to breast cancer prevention and screening.
Open AccessGuidance for the Clinical Use of the Breast Cancer Polygenic Risk Scores
Background/Objectives: Polygenic risk scores (PRSs) have been extensively studied and are increasingly applied in healthcare. One of the most studied and developed areas is predictive medicine for breast cancer, but there is no wider consensus on the indications for the clinical use of PRSs for breast cancer. This current guidance endeavours to articulate the scientific evidence underpinning the clinical utility of PRSs in stratifying breast cancer risk, with a particular emphasis on clinical application. Methods: This guidance has been prepared by a group of experts who have been active in breast cancer PRS research and development, combining a review of the evidence base with expert opinion for indications for clinical use. Results: Based on data from various studies and existing breast cancer prevention and screening services, the indications for clinical use of breast cancer PRSs can be divided into the following scenarios: (1) Management of cancer-free women with a family history of cancer; (2) individual personalised breast cancer prevention and screening in healthcare services; and (3) breast cancer screening programs for more personalised screening. Conclusions: The integration of PRSs into clinical practice enables healthcare providers to deliver more accurate risk assessments, personalised prevention strategies, and optimised screening programmes, thereby improving patient outcomes and enhancing the effectiveness of breast cancer care. PRS testing represents a novel component in clinical breast cancer risk assessment, supporting a personalised, risk-based approach to breast cancer prevention and screening.
- Open Access
- 5 December 2024
- Published by MDPI AG in Preprints.org
Guidance for the Clinical Use of the Breast Cancer Polygenic Risk Score
Background/Objectives: Polygenic risk scores (PRSs) have been extensively studied and are in-creasingly applied in healthcare. One of the most studied and developed areas is predictive med-icine for breast cancer, but there is no wider consensus on the indications for the clinical use of PRSs for breast cancer. Current guidance endeavours to articulate the scientific evidence under-pinning the clinical utility of PRS in stratifying breast cancer risk, with a particular emphasis on clinical application. Methods: The guidance has been prepared by a group of experts who have been active in breast cancer PRS research and development, combining a review of the evidence base with expert opin-ion for indications for clinical use. Results: Based on data from various studies and existing breast cancer prevention and screening services, the indications for clinical use of breast cancer PRS can be divided into the following scenarios: 1) Management of cancer-free women with a family history of cancer; 2) Individual personalised breast cancer prevention and screening in healthcare services; 3) Breast cancer screening programs for more personalised screening. Conclusions: The integration of PRS into clinical practice enables healthcare providers to deliver more accurate risk assessments, personalised prevention strategies, and optimised screening programmes, thereby improving patient outcomes and enhancing the effectiveness of breast cancer care. PRS testing represents a novel component in clinical breast cancer risk assessment, support-ing a personalised, risk-based approach to breast cancer prevention and screening.
- 5 December 2024
- Published by MDPI AG in Preprints.org
Open AccessGuidance for the Clinical Use of the Breast Cancer Polygenic Risk Score
Background/Objectives: Polygenic risk scores (PRSs) have been extensively studied and are in-creasingly applied in healthcare. One of the most studied and developed areas is predictive med-icine for breast cancer, but there is no wider consensus on the indications for the clinical use of PRSs for breast cancer. Current guidance endeavours to articulate the scientific evidence under-pinning the clinical utility of PRS in stratifying breast cancer risk, with a particular emphasis on clinical application. Methods: The guidance has been prepared by a group of experts who have been active in breast cancer PRS research and development, combining a review of the evidence base with expert opin-ion for indications for clinical use. Results: Based on data from various studies and existing breast cancer prevention and screening services, the indications for clinical use of breast cancer PRS can be divided into the following scenarios: 1) Management of cancer-free women with a family history of cancer; 2) Individual personalised breast cancer prevention and screening in healthcare services; 3) Breast cancer screening programs for more personalised screening. Conclusions: The integration of PRS into clinical practice enables healthcare providers to deliver more accurate risk assessments, personalised prevention strategies, and optimised screening programmes, thereby improving patient outcomes and enhancing the effectiveness of breast cancer care. PRS testing represents a novel component in clinical breast cancer risk assessment, support-ing a personalised, risk-based approach to breast cancer prevention and screening.